The potential of combined shear wave and strain elastography to reduce unnecessary biopsies in breast cancer diagnostics – An international, multicentre trial

2022 ◽  
Vol 161 ◽  
pp. 1-9
Author(s):  
Michael Golatta ◽  
André Pfob ◽  
Christopher Büsch ◽  
Thomas Bruckner ◽  
Zaher Alwafai ◽  
...  
Author(s):  
Mehdi Nikkhah ◽  
Jeannine S. Strobl ◽  
Bhanu Peddi ◽  
Adedamola Omotosho ◽  
Masoud Agah

In this paper we are investigating three dimensional (3-D) silicon-based microenvironments as potential platforms for breast cancer diagnostics. We have developed isotropically etched microstructures with a wide range of geometrical patterns for this purpose. Our results indicate that with the etched surface ratio of ∼65%, it is possible to capture 80–90% of the cancer cells within each silicon chip. After treatment of the cells with mitomycin C (to block the cell growth) more number of the cells are trapped inside the etched features for longer cultures times (72 h) suggesting that there is a directed motility and attraction of the cells toward the etched cavities and by optimally designing the etched features, the proposed platforms can be potentially used for diagnostics purposes.


Author(s):  
E.A. Sergeeva ◽  
V.V. Dudenkova ◽  
S.S. Kuznetsov ◽  
M.Yu. Kirillin ◽  
M.V. Pavlov ◽  
...  

Breast Care ◽  
2008 ◽  
Vol 3 (6) ◽  
pp. 384-387 ◽  
Author(s):  
Felix Diekmann ◽  
Susanne Diekmann

2018 ◽  
Vol 272 ◽  
pp. 626-633 ◽  
Author(s):  
Erika Chocholova ◽  
Tomas Bertok ◽  
Lenka Lorencova ◽  
Alena Holazova ◽  
Pavol Farkas ◽  
...  

2008 ◽  
Vol 141 (3) ◽  
pp. 145-148 ◽  
Author(s):  
B. Brożek-Płuska ◽  
I. Placek ◽  
K. Kurczewski ◽  
Z. Morawiec ◽  
M. Tazbir ◽  
...  

2013 ◽  
Vol 5 ◽  
pp. BIC.S9455 ◽  
Author(s):  
Muaiad Kittaneh ◽  
Alberto J. Montero ◽  
Stefan Glück

In recent years advances in molecular biology have launched disruptive innovations in breast cancer diagnostics and therapeutics. The advent of genomics has revolutionized our understanding of breast cancer as several different biologically and molecularly distinct diseases. This research has led to commercially available polymerase chain reaction (PCR) and microarray tests that have begun to fundamentally change the way medical oncologists quantify recurrence risk in early stage breast cancer patients. The Genomics era has altered the clinicopathologic paradigm of selecting patients for adjuvant cytotoxic chemotherapy. Sufficiently powered prospective studies are underway that may establish these molecular assays as elements of standard clinical practice in breast cancer treatment. In this article, we review the strengths and limitations of currently available breast cancer-specific molecular tests.


Sign in / Sign up

Export Citation Format

Share Document